Drugs / TERN-501
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT05415722 | Jun 2022 → Jul 2023 | metabolic dysfunction-associated steatohepatitis | Terns, Inc. | Completed | Met primary |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | TERN-501 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05415722 ↗ |
| Action | Activate | “TERN-501 (THRβ agonist)” PMID 40500414 ↗ Jun 2025 |
| Route | Oral | “Orally administered.” NCT05415722 ↗ |